Holen Sie sich die Stockscreener-App
1.51
7.93%
-0.13
Acrivon Therapeutics Inc Aktie (ACRV) Neueste Nachrichten
Q1 Earnings Forecast for ACRV Issued By HC Wainwright - Defense World
Acrivon Therapeutics (NASDAQ:ACRV) and Astellas Pharma (OTCMKTS:ALPMY) Head to Head Contrast - Defense World
H.C. Wainwright maintains Acrivon stock Buy rating, $19 target By Investing.com - Investing.com Australia
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know - MSN
Acrivon Therapeutics price target lowered to $10 from $18 at Oppenheimer - TipRanks
Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks - Yahoo Finance
H.C. Wainwright maintains Acrivon stock Buy rating, $19 target - Investing.com India
HC Wainwright Has Lowered Expectations for Acrivon Therapeutics (NASDAQ:ACRV) Stock Price - Defense World
FY2029 Earnings Estimate for ACRV Issued By HC Wainwright - Defense World
Cantor Fitzgerald Reaffirms “Overweight” Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics reports Q4 EPS (60c), consensus (70c) - TipRanks
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Hard-to-Treat Endometrial Cancer - Stock Titan
Acrivon Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Long Term Trading Analysis for (ACRV) - news.stocktradersdaily.com
Acrivon narrows focus for ACR-368 in endometrial cancer - BioWorld MedTech
JMP maintains Acrivon stock with $17 target following update By Investing.com - Investing.com Australia
Acrivon Therapeutics stock target cut to $19 by H.C. Wainwright - Investing.com South Africa
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Crude Oil Gains Over 1%; Cintas Shares Jump After Q3 Earnings - Benzinga
Nasdaq Down 1%; Dollar Tree To Sell Family Dollar Business For $1 Billion - Benzinga
Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer - Endpoints News
Cantor Fitzgerald maintains Overweight on Acrivon stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains Overweight on Acrivon stock - Investing.com
JMP maintains Acrivon stock with $17 target following update - Investing.com India
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Acrivon Therapeutics’ SWOT analysis: innovative oncology firm’s stock potential By Investing.com - Investing.com Australia
Citizens JMP reiterates Acrivon stock with $17 target By Investing.com - Investing.com South Africa
Acrivon Therapeutics’ SWOT analysis: innovative oncology firm’s stock potential - Investing.com
Citizens JMP reiterates Acrivon stock with $17 target - Investing.com
Acrivon Therapeutics: Promising Oncology Advancements and Strategic Positioning Justify Buy Rating - TipRanks
Acrivon Therapeutics (ACRV) to Release Quarterly Earnings on Thursday - Defense World
Acrivon Therapeutics to Host Corporate R&D Event to Provide - GlobeNewswire
Acrivon Unveils Next-Gen Cancer Platform: Key Updates from Leading Oncology Experts - StockTitan
Acrivon Therapeutics to Host Virtual R&D Event on March 25, 2025, Featuring Updates on ACR-368 and ACR-2316 - Nasdaq
Acrivon Therapeutics Names Adam Levy as CFO -March 17, 2025 at 05:36 am EDT - Marketscreener.com
(ACRV) Investment Report - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Down 33.7% in February - The AM Reporter
Acrivon Therapeutics appoints new CFO as predecessor steps down By Investing.com - Investing.com Australia
Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Decreases By 33.7% - Defense World
Acrivon Therapeutics appoints new CFO as predecessor steps down - Investing.com
Acrivon Therapeutics Appoints New Chief Financial Officer - TipRanks
Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Price Target at $23.67 - Defense World
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):